NOTE 5 – SHARE-BASED PAYMENTS:

Restricted Stock Awards

Restricted stock awards (“RSAs”) have been granted to employees. The value of an RSA award is based on the Company’s share price on the date of grant. The Company granted RSAs in accordance with the Incentive Plan.

The following table summarizes the Company’s RSA activity for the six months ended June 30, 2026, as described above, relating to the RSAs granted pursuant to the Incentive Plan:

​

​

As of June 30, 2026, there was $8.0 million of total unrecognized compensation cost related to RSAs expected to be recognized over a weighted average period of 1.63 years.

On January 6, 2026, the Company issued 150,000 RSAs to each of Mr. Bentsur, Dr. Poradosu, and Mr. Shemesh. These RSAs vest over three years, with one-third vesting on each anniversary of the grant date, conditioned upon their continued service.

On January 2, 2025, the Company issued 250,000 RSAs to Mr. Bentsur, and 150,000 RSAs to each of Dr. Poradosu and Mr. Shemesh (the “January 2025 Grants”). These RSAs vest over three years, with one-third vesting on each anniversary of the grant date. On January 6, 2026, the vesting of the first one-third of the January 2025 Grants was extended to July 15, 2026, conditioned upon their continued service. On July 7, 2026, the vesting of the first one-third of the January 2025 Grants was extended to December 11, 2026, conditioned upon their continued service.

On January 4, 2024, the Company issued 130,000 RSAs to each of Dr. Poradosu and Mr. Shemesh (the “January 2024 Grants”). These RSAs vest over three years, with one-third vesting on each anniversary of the grant date, conditioned upon their continued service. On January 6, 2026, the vesting of the first two-thirds of the January 2024 Grants was

extended to July 15, 2026, and the final third vests January 4, 2027. On July 7, 2026, the vesting of the first two-thirds of the January 2024 Grants was extended to December 11, 2026, conditioned upon their continued service.

On January 12, 2023, the Company issued 210,000 RSAs to Mr. Bentsur and 115,000 RSAs to each of Dr. Poradosu and Mr. Shemesh (the “January 2023 Grants”). These RSAs vest over three years, with one-third vesting on each anniversary of the grant date, conditioned upon their continued service. On January 6, 2026, the full vesting of the January 2023 Grants was extended to July 15, 2026.  On July 7, 2026, the full vesting of the January 2023 Grants was extended to December 11, 2026, conditioned upon their continued service.

On April 1, 2022, the Company issued 120,000 RSAs to Mr. Bentsur and 60,000 RSAs to each of Dr. Poradosu and Mr. Shemesh (the “April 2022 Grants”). These RSAs vest over three years, with one-third vesting on each anniversary of the grant date, conditioned upon their continued service.  On January 6, 2026, the full vesting of the April 2022 Grants was extended to July 15, 2026. On July 7, 2026, the full vesting of the April 2022 Grants was extended to December 11, 2026, conditioned upon their continued service.

On July 27, 2021, Mr. Bentsur, Dr. Poradosu, and Mr. Shemesh were granted 96,759, 48,399, and 48,399 RSAs, respectively, which were not part of the Incentive Plan and excluded from the table above.  On January 6, 2026, the vesting of the July 2021 grants to Mr. Bentsur, Dr. Poradosu and Mr. Shemesh was extended to July 15, 2026. On July 7, 2026, the full vesting of the July 2021 Grants was extended to December 11, 2026, conditioned upon their continued service.

Share Compensation Expense

For the three months ended June 30, 2026, the Company recognized expenses of $0.6 million as part of general and administrative expenses and $1.1 million as part of research and development expenses. For the three months ended June 30, 2025, the Company recognized expenses of $0.9 million as part of general and administrative expenses and $0.9 million as part of research and development expenses. For the six months ended June 30, 2026, the Company recognized expenses of $1.3 million as part of general and administrative expenses and $2.3 million as part of research and development expenses. For the six months ended June 30, 2025, the Company recognized expenses of $1.9 million as part of general and administrative expenses and $1.7 million as part of research and development expenses.